B

Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315

Watchlist Manager
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Watchlist
Price: 8.25 HKD -2.02%
Market Cap: 3.3B HKD
Have any thoughts about
Biocytogen Pharmaceuticals Beijing Co Ltd?
Write Note

Net Margin
Biocytogen Pharmaceuticals Beijing Co Ltd

-30.5%
Current
-55%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-30.5%
=
Net Income
-243.8m
/
Revenue
800.6m

Net Margin Across Competitors

Country CN
Market Cap 3.4B HKD
Net Margin
-30%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 310.3B USD
Net Margin
9%
Country US
Market Cap 141.6B USD
Net Margin
13%
Country US
Market Cap 115.3B USD
Net Margin
0%
Country US
Market Cap 102.4B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 134.3B AUD
Net Margin
18%
Country US
Market Cap 77.3B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36.2B EUR
Net Margin
-14%
No Stocks Found

Biocytogen Pharmaceuticals Beijing Co Ltd
Glance View

Market Cap
3.3B HKD
Industry
Biotechnology

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. The company is headquartered in Beijing, Beijing. The company went IPO on 2022-09-01. The firm operates two business segments. The Drug Development Business segment is mainly engaged in the research and development of oncology and autoimmune disease treatments, as well as antibody development. The Preclinical Research Service segment is mainly engaged in gene editing, preclinical pharmacological efficacy evaluation and model animal sales.

Intrinsic Value
11.08 HKD
Undervaluation 26%
Intrinsic Value
Price
B

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-30.5%
=
Net Income
-243.8m
/
Revenue
800.6m
What is the Net Margin of Biocytogen Pharmaceuticals Beijing Co Ltd?

Based on Biocytogen Pharmaceuticals Beijing Co Ltd's most recent financial statements, the company has Net Margin of -30.5%.